Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYZFNH)

Drug Name
Sapanisertib Drug Info
Synonyms INK-128; MLN0128; INK 128; INK128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; MLN-0128; JGH0DF1U03
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 2 [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [2]
Therapeutic Class
Antiviral Agents
Cross-matching ID
PubChem CID
45375953
ChEBI ID
CHEBI:91450
CAS Number
CAS 1224844-38-5
TTD Drug ID
DMYZFNH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting HUMAN mammalian target of rapamycin (mTOR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sirolimus DMGW1ID Advanced cancer 2A00-2F9Z Approved [3]
Everolimus DM8X2EH Advanced cancer 2A00-2F9Z Approved [4]
Rapamycin DM8GRJK Lymphangioleiomyomatosis CB07 Investigative [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HUMAN mammalian target of rapamycin (mTOR) TT7HQAF MTOR_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT02049957) Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer. U.S. National Institutes of Health.
2 Prevent COVID-19 Severity by Repurposing mTOR Inhibitors. 2 April 2020
3 Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020 Mar 16;6:14.
4 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.